 SAN DIEGO, June 02, 2021 GLOBE NEWSWIRE -- Metacrine, Inc. NASDAQ:MTCR, a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin Jardiance, a sodium-glucose cotransport-2 SGLT2 inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis NASH. The Company plans to report topline data in the fourth quarter of 2021. 